Tumor Banking for the Southwest Oncology Group

描述(由申请人提供)： 这项申请是由西南肿瘤学小组(SWOG)为响应NCI颁发的RFA而准备的，目的是提供和加强所需的基础设施，以确保收集、存储和获取从NCI资助的临床试验的患者群体收集的高质量、注释良好的人类样本和具有代表性的样本。强大的分子技术的出现和靶向治疗的出现为开发更有效的癌症患者个体化治疗打开了大门。获得相关的高质量临床、治疗、复发和结果数据的标本对于开发和验证诊断、目标识别和治疗反应预测所需的测试至关重要。在全面分析癌症发生和发展的关键途径的基础上，开发和有效地利用癌症干预措施，需要获得在前瞻性随机试验中接受治疗的患者的生物显微镜。高质量的统一采集的样本库以及经过验证的临床和结果数据对于开发和提供新的诊断和预测工具至关重要，这些工具对于消除癌症造成的痛苦和死亡至关重要。与各种疾病和相关科学委员会及其临床试验一起，我们正在开发多种方法来收集和分析与肿瘤相关的生物标本。 具体目标1：提供高质量、注解良好的组织和其他生物标本，收集自NCI赞助的临床试验的患者并具有代表性，用于研究目的。 具体目标2：提供有关标本收藏的信息，以供潜在的研究用途。 具体目标3：根据标本的可获得性和申请使用标本的科学价值，增加获得SWOG试验相关生物检疫剂的机会。 具体目标4：与NCI和其他合作小组合作，执行集团银行委员会(GBC)发起的政策和程序。 具体目标5：分享关于SWOG生物谱库中可获得的材料和使用标本产生的重大科学见解的数据。

DESCRIPTION (provided by applicant): This application is being prepared by the Southwest Oncology Group (SWOG) in response to the NCI-issued RFA to provide and enhance the infrastructure needed to ensure the collection of, storage of and access to high-quality, well-annotated human specimens collected from and representative of the patient populations entered into NCI-funded clinical trials. The advent of powerful molecular technologies and the emergence of targeted therapeutics have opened the door to developing more effective and in some cases, individualized treatments of patients with cancer. Access to specimens with associated high-quality clinical, treatment, recurrence and outcome data is critical to developing and validating the tests needed for diagnosis, target identification and prediction of response to therapy. Developing and effectively utilizing cancer interventions based on the comprehensive analysis of critical pathways of cancer initiation and progression require access to biospecimens from patients treated in prospective randomized trials. High quality banks of uniformly collected specimens with validated clinical and outcome data are essential for the development and delivery o new diagnostic and predictive tools that are critical to eliminating the suffering and death due to cancer. Together with the various Disease and Correlative Science Committees and their clinical trials, we are developing multiple approaches to the collection and analysis of tumor-related biospecimens. Specific Aim 1: To provide high quality, well-annotated tissues and other biospecimens collected from and representative of the patients entered in NCI-sponsored clinical trials for research purposes. Specific Aim 2: To provide information about the specimen collections for potential research use. Specific Aim 3: To increase access to SWOG trial-related biospecimens based on specimen availability and the scientific merit of applications to use the specimens. Specific Aim 4: To work with the NCI and the other cooperative groups to implement the policies and procedures initiated by the Group Banking Committee (GBC). Specific Aim 5: To share data on both the material that is available in the SWOG biospecimens banks and the major scientific insights generated from the use of the specimens.